A Study to Assess Treat-to-Target and Dosing Flexibility of Oral Upadacitinib Tablets in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT05507580
·
clinicaltrials.gov ↗
PHASE4
Phase
COMPLETED
Status
461
Enrollment
INDUSTRY
Sponsor class
Conditions
Atopic Dermatitis
Interventions
DRUG:
Upadacitinib
Sponsor
AbbVie